AMI Asset Management Corp Has $16.70 Million Position in Ligand Pharmaceuticals Inc. (LGND)

AMI Asset Management Corp decreased its holdings in Ligand Pharmaceuticals Inc. (NASDAQ:LGND) by 13.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 121,964 shares of the biotechnology company’s stock after selling 18,794 shares during the period. AMI Asset Management Corp owned 0.58% of Ligand Pharmaceuticals worth $16,701,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Bank of Montreal Can lifted its stake in Ligand Pharmaceuticals by 1,202.1% in the fourth quarter. Bank of Montreal Can now owns 9,922 shares of the biotechnology company’s stock worth $1,359,000 after purchasing an additional 9,160 shares during the last quarter. Convergence Investment Partners LLC lifted its stake in Ligand Pharmaceuticals by 9.0% in the fourth quarter. Convergence Investment Partners LLC now owns 14,712 shares of the biotechnology company’s stock worth $2,015,000 after purchasing an additional 1,210 shares during the last quarter. Louisiana State Employees Retirement System lifted its stake in Ligand Pharmaceuticals by 7.1% in the fourth quarter. Louisiana State Employees Retirement System now owns 9,100 shares of the biotechnology company’s stock worth $1,246,000 after purchasing an additional 600 shares during the last quarter. Atlantic Trust Group LLC lifted its stake in Ligand Pharmaceuticals by 1.8% in the third quarter. Atlantic Trust Group LLC now owns 143,839 shares of the biotechnology company’s stock worth $19,585,000 after purchasing an additional 2,540 shares during the last quarter. Finally, Parametric Portfolio Associates LLC lifted its stake in Ligand Pharmaceuticals by 7.7% in the third quarter. Parametric Portfolio Associates LLC now owns 202,029 shares of the biotechnology company’s stock worth $27,506,000 after purchasing an additional 14,435 shares during the last quarter.

Several brokerages have issued reports on LGND. HC Wainwright set a $169.00 price objective on shares of Ligand Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday. Craig Hallum reissued a “buy” rating and issued a $170.00 price objective (up previously from $160.00) on shares of Ligand Pharmaceuticals in a research note on Wednesday, November 15th. Roth Capital reissued a “buy” rating and issued a $158.00 price objective (up previously from $135.00) on shares of Ligand Pharmaceuticals in a research note on Wednesday, October 11th. Zacks Investment Research raised shares of Ligand Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $165.00 price objective for the company in a research note on Thursday, October 12th. Finally, BidaskClub raised shares of Ligand Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, January 5th. Two analysts have rated the stock with a sell rating, one has issued a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $150.67.

In other news, Director Stephen L. Sabba sold 925 shares of the firm’s stock in a transaction that occurred on Wednesday, December 20th. The shares were sold at an average price of $137.25, for a total transaction of $126,956.25. Following the transaction, the director now directly owns 26,985 shares of the company’s stock, valued at $3,703,691.25. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director John W. Kozarich sold 2,500 shares of the firm’s stock in a transaction that occurred on Wednesday, January 10th. The stock was sold at an average price of $145.00, for a total transaction of $362,500.00. Following the transaction, the director now directly owns 33,149 shares in the company, valued at $4,806,605. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 20,253 shares of company stock worth $2,884,507. Corporate insiders own 8.30% of the company’s stock.

Shares of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) traded down $2.51 during trading hours on Tuesday, hitting $146.39. 188,315 shares of the stock were exchanged, compared to its average volume of 211,710. The stock has a market capitalization of $3,130.00, a price-to-earnings ratio of 212.16, a PEG ratio of 1.59 and a beta of 0.91. Ligand Pharmaceuticals Inc. has a fifty-two week low of $95.08 and a fifty-two week high of $151.67. The company has a current ratio of 0.97, a quick ratio of 0.95 and a debt-to-equity ratio of 0.05.

Ligand Pharmaceuticals (NASDAQ:LGND) last issued its earnings results on Thursday, November 9th. The biotechnology company reported $0.69 EPS for the quarter, topping the Zacks’ consensus estimate of $0.37 by $0.32. The business had revenue of $33.38 million for the quarter, compared to analyst estimates of $31.04 million. Ligand Pharmaceuticals had a net margin of 12.76% and a return on equity of 7.83%. The company’s quarterly revenue was up 54.4% compared to the same quarter last year. During the same period last year, the company posted $0.62 earnings per share. sell-side analysts expect that Ligand Pharmaceuticals Inc. will post 3.15 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “AMI Asset Management Corp Has $16.70 Million Position in Ligand Pharmaceuticals Inc. (LGND)” was originally published by TrueBlueTribune and is owned by of TrueBlueTribune. If you are viewing this piece of content on another site, it was illegally stolen and republished in violation of United States and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.truebluetribune.com/2018/01/16/ami-asset-management-corp-has-16-70-million-position-in-ligand-pharmaceuticals-inc-lgnd.html.

About Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals.

Institutional Ownership by Quarter for Ligand Pharmaceuticals (NASDAQ:LGND)

Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply